Stoke Therapeutics (NASDAQ:STOK) Reaches New 12-Month High at $33.00

Stoke Therapeutics (NASDAQ:STOK) reached a new 52-week high during trading on Thursday . The company traded as high as $33.00 and last traded at $33.00, with a volume of 130 shares trading hands. The stock had previously closed at $31.92.

A number of research firms have commented on STOK. Canaccord Genuity began coverage on Stoke Therapeutics in a research report on Monday, July 15th. They issued a “buy” rating and a $44.00 price target on the stock. Credit Suisse Group began coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set an “outperform” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set an “overweight” rating and a $34.00 target price on the stock. Finally, Cowen restated a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, August 15th.

The company’s 50-day moving average price is $26.86.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 14th. The company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.58). Research analysts forecast that Stoke Therapeutics will post -2.28 earnings per share for the current year.

In other news, major shareholder Rtw Investments, Lp purchased 555,556 shares of the company’s stock in a transaction that occurred on Wednesday, June 19th. The shares were acquired at an average cost of $18.00 per share, with a total value of $10,000,008.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Apple Tree Partners Iv, L.P. purchased 1,388,889 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $25,000,002.00. The disclosure for this purchase can be found here.

A number of hedge funds have recently bought and sold shares of the stock. Cormorant Asset Management LP acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $54,539,000. Perceptive Advisors LLC acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $19,601,000. Janus Henderson Group PLC acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $11,668,000. Price T Rowe Associates Inc. MD acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $10,994,000. Finally, Orbimed Advisors LLC acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $3,792,000. 10.21% of the stock is currently owned by institutional investors and hedge funds.

About Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Recommended Story: Do equity income investments outperform growth and income investments?

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.